There are already several gut peptide mimetics such as GLP-1, DDP IV inhibitors, CCK antagonists, PYY, PP in clinical trials for obesity and diabetes (211). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.